Table 2.
Association of CHD1L expression with patient's clinico-pathological features in 160 ovarian carcinomas
| All cases | CHD1L protein | |||
|---|---|---|---|---|
| Normal expression | Overexpression | P value a | ||
| Age at surgery (years) | 0.620 | |||
| <51.0 b | 82 | 40 (49%) | 42 (51%) | |
| ≥51.0 | 78 | 35 (45%) | 43 (55%) | |
| Histological type | 0.024 | |||
| Serous | 106 | 43 (41%) | 63 (59%) | |
| Mucinous | 19 | 14 (74%) | 5 (26%) | |
| Othersc | 35 | 18 (51%) | 17 (49%) | |
| Histological grade (Silveberg) | 0.142 | |||
| G1 | 28 | 16 (57%) | 12 (43%) | |
| G2 | 89 | 44 (49%) | 45 (51%) | |
| G3 | 43 | 15 (35%) | 28 (65%) | |
| pT status | <0.001 | |||
| pT1 | 38 | 29 (76%) | 9 (24%) | |
| pT2 | 35 | 15 (43%) | 20 (57%) | |
| pT3 | 87 | 31 (36%) | 56 (64%) | |
| pN status | <0.001 | |||
| pN0 | 77 | 50 (65%) | 27 (35%) | |
| pN1 | 83 | 25 (30%) | 58 (70%) | |
| pM status | 0.013 | |||
| pMX | 135 | 69 (51%) | 66 (49%) | |
| pM1 | 25 | 6 (24%) | 19 (76%) | |
| FIGO stage | <0.001 | |||
| I | 25 | 20 (92%) | 5 (20%) | |
| II | 21 | 13 (52%) | 8 (38%) | |
| III | 89 | 36 (40%) | 53 (60%) | |
| IV | 25 | 6 (24%) | 19 (76%) | |
a Chi-square test;
b Mean age;
c Endometrioid, Clear cell and Undifferentiated types.